Researchers from the Stanford University School of Medicine used LC Sciences’ miRNA microarray service to show that microRNA-210 was highly expressed in live mouse HL-1 cardiomyocytes compared with apoptotic cells after 48 hours of hypoxia exposure. Gain-of-function and loss-of-function approaches were used to investigate microRNA-210 therapeutic potential in vitro.

Adult FVB mice underwent intramyocardial injections with minicircle vector carrying microRNA-210 precursor, minicircle carrying microRNA-scramble, or sham surgery. At 8 weeks, echocardiography showed a significant improvement of left ventricular fractional shortening in the minicircle vector carrying microRNA-210 precursor group compared with the minicircle carrying microRNA-scramble control.

MicroRNA-210 represents a potential novel therapeutic approach for treatment of ischemic heart disease.

 

Evaluation of cardiac function after MI after miR-210 treatment

LC Sciences

 

A, Representative echocardiogram of mice with LAD ligation after injection of MC-210, MC-Scr, or sham group at Week 8. B, Quantitative analysis of left ventricular FS among the 3 groups. C, Representative Masson trichrome staining of explanted heart at Week 8 showed increased wall thickness for the MC-210 group, confirming the positive functional imaging data seen in echocardiography. D, TUNEL staining of an explanted heart demonstrated significantly reduced apoptotic cells in MC-210 group compared with the MC-Scr control group. E, Immunofluorescence staining of CD31 endothelial marker (green) demonstrated increased neovascularization in the myocardium after MC-210 delivery compared with the MC-Scr control.

 

Related Service

miRNA Microarray Service – LC Sciences provides a microRNA (miRNA) expression profiling service using microarrays based on our in-house developed µParaflo® technology platform. We have standard arrays for all mature miRNAs of all species available in the latest version of the miRBase database (Release 21, July 2014). Our service is comprehensive and includes sample labeling, array hybridization, image data processing and in-depth data analysis. Two-three weeks after receiving your total RNA samples, we’ll send you both the raw and fully analyzed data. [Learn more…]

Reference

Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA, Fasanaro P, Sun N, Wang X, Martelli F, Robbins RC, Wu JC. (2010) MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 122(11 Suppl), S124-31. [article]